[ad_1]
Company has additionally accomplished the in-house encapsulation of 5mg & 10mg psilocybin extract dosage codecs
VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a number one Health Canada licensed psychedelics pharmaceutical producer, specializing in managed substances corresponding to pure psilocybin and MDMA, is happy to announce that three validation batches of its Natural Psilocybin Extract have undergone full launch testing and have been issued the Certificate of Analysis (COA) by a third-party, confirming compliance with Good Manufacturing Practice (GMP) specs. Additionally, the Company has efficiently accomplished the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage codecs.
The third-party COA confirms essential data relating to efficiency, water content material, microbial content material, and heavy steel content material, guaranteeing that the Natural Psilocybin Extract meets the predetermined specs. The completion of each extract validation and completed product testing aligns with Optimi’s purpose of advancing the drug candidate, marking vital progress towards its eventual launch for human consumption.
“This is an exciting development for Optimi,” mentioned CEO Bill Ciprick. “Obtaining successful results on the validation batches of psilocybin extract speaks to Optimi’s dedication to developing a repeatable, quality focused manufacturing process. This documentation provides important data and helps Optimi ensure patients receive an extract backed by evidence,” added Ciprick.
Ciprick additionally said, “We are able to create stable GMP inventory in-house and at scale which showcases Optimi’s unique position in the psychedelic supply chain. We’ve worked hard to secure the end-to-end production advantage.”
After six months of accelerated information assortment, Optimi confirms that its Natural Psilocybin Extract maintained its unique efficiency stage with none degradation throughout stability testing. Furthermore, the Psilocybe cubensis mushrooms utilized in creating the extract had been cultivated in-house beneath Good Agricultural Collection Practice (GACP) situations, as highlighted in a latest video from earlier this 12 months.
As the Company prepares to fulfill its Australian provide commitments with Mind Medicine Australia, Karina Lahnakoski, Optimi’s Director of Quality and Commercial Strategies, assures sufferers and therapists of the reliability and high quality of Optimi’s drug candidates.
“Our drug development program for the Natural Psilocybin Extract has established a robust process which has been validated and confirmed through the COA testing and the stability program,” mentioned Lahnakoski. “By conducting our program in accordance with guidelines established by organizations like the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and the requirements of Good Manufacturing Practice (GMP), we further emphasize our commitment to patient safety and high-quality products.”
Dedicated to fostering collaborations and advancing the scientific understanding of the potential therapeutic advantages of psilocybin, Optimi welcomes inquiries from principal investigators and analysis teams concerned with studying extra in regards to the Company’s validated GMP Natural Psilocybin Extract and different drug candidates.
For media inquiries, please contact Michael Kydd:
michaelk@optimihealth.ca
902.880.6121
For investor inquiries, please contact:
investors@optimihealth.ca
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
Optimi Health Corp. an end-to-end drug researcher and formulator licensed by Health Canada to supply and provide, for scientific analysis functions, psychedelic substances corresponding to 3,4-Methylenedioxymethamphetamine (“MDMA”), pure GMP-grade psilocybin, in addition to useful mushrooms that target the well being and wellness markets. Built with the aim of manufacturing scalable psychedelic formulations for transformational human experiences, the Company’s purpose is to be the primary trusted, compassionate provider of protected drug candidates all through the world. Optimi’s merchandise are grown and manufactured at its two amenities comprising a complete of 20,000 sq. ft in Princeton, British Columbia.
FORWARD‐LOOKING STATEMENTS
This information launch comprises forward-looking statements and forward-looking data inside the which means of Canadian securities laws (collectively, “forward-looking statements”) that relate to Optimi’s present expectations and views of future occasions. Any statements that specific, or contain discussions as to, expectations, beliefs, plans, targets, assumptions or future occasions or efficiency (usually, however not all the time, via the usage of phrases or phrases corresponding to “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are usually not historic details and could also be forward-looking statements and will contain estimates, assumptions and uncertainties which may trigger precise outcomes or outcomes to vary materially from these expressed in such forward-looking statements. No assurance may be on condition that these expectations will show to be right and such forward-looking statements included on this information launch shouldn’t be unduly relied upon. These statements communicate solely as of the date of this information launch.
Forward-looking statements are primarily based on quite a lot of assumptions and are topic to quite a lot of dangers and uncertainties, a lot of that are past Optimi’s management, which may trigger precise outcomes and occasions to vary materially from these which can be disclosed in or implied by such forward-looking statements. Such dangers and uncertainties embrace, however are usually not restricted to, the affect and development of the COVID-19 pandemic and different components set forth beneath “Forward-Looking Statements” and “Risk Factors” within the Company’s Annual Information Form dated January 31, 2024, and different steady disclosure filings out there beneath Optimi’s profile at www.sedarplus.ca. Optimi undertakes no obligation to replace or revise any forward-looking statements, whether or not because of new data, future occasions or in any other case, besides as could also be required by regulation. New components emerge on occasion, and it’s not potential for Optimi to foretell all of them or assess the affect of every such issue or the extent to which any issue, or mixture of things, might trigger outcomes to vary materially from these contained in any forward-looking assertion.
Any forward-looking statements contained on this information launch are expressly certified of their entirety by this cautionary assertion.
[adinserter block=”4″]
[ad_2]
Source link